Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The ANZCTR website will be unavailable from 1pm until 3pm (AEDT) on Wednesday the 30th of October for website maintenance. Please be sure to log out of the system in order to avoid any loss of data.
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial details imported from ClinicalTrials.gov
For full trial details, please see the original record at
https://clinicaltrials.gov/study/NCT05863442
Registration number
NCT05863442
Ethics application status
Date submitted
17/03/2023
Date registered
18/05/2023
Date last updated
24/11/2023
Titles & IDs
Public title
Comparative PK, Safety, Tolerability, Immunogenicity, and PD Profile Study of TUR03 and Soliris in Healthy Participants
Query!
Scientific title
A First-in-human, Randomized, Double-blind, Parallel-group Study to Evaluate the PK, Safety, Tolerability, Immunogenicity, and PD Profile of a Single Intravenous Dose of TUR03 Compared With Soliris® in Healthy Adult Male Participants
Query!
Secondary ID [1]
0
0
TUR03-22-01
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Healthy
0
0
Query!
Condition category
Condition code
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
Treatment: Drugs - Soliris 300 MG in 30 ML Injection
Treatment: Drugs - TUR03 300 MG in 30 ML Injection
Active comparator: Soliris -
Experimental: TUR03 -
Treatment: Drugs: Soliris 300 MG in 30 ML Injection
Active Comparator
Treatment: Drugs: TUR03 300 MG in 30 ML Injection
Investigational medicinal Product, eculizumab - Turgut
Query!
Intervention code [1]
0
0
Treatment: Drugs
Query!
Comparator / control treatment
Query!
Control group
Query!
Outcomes
Primary outcome [1]
0
0
PK similarity of TUR03 and Soliris following a single IV infusion in healthy participants
Query!
Assessment method [1]
0
0
The primary endpoint for PK similarity is AUC(0-inf).
Query!
Timepoint [1]
0
0
Day 1 - Day 57
Query!
Secondary outcome [1]
0
0
Eculizumab serum concentration-time profile
Query!
Assessment method [1]
0
0
Serum eculizumab concentrations will be listed and summarized using descriptive statistics by treatment group and nominal PK sampling time point. All serum eculizumab concentrations that are below the limit of quantification will be labeled as such in the concentration data listings. Individual and arithmetic mean (per treatment) concentration-time profiles will also be presented graphically.
Query!
Timepoint [1]
0
0
Day 1 - Day 57
Query!
Secondary outcome [2]
0
0
Maximum serum concentration (Cmax)
Query!
Assessment method [2]
0
0
Observed concentration versus time data
Query!
Timepoint [2]
0
0
Day 1- Day 57
Query!
Secondary outcome [3]
0
0
Area under the concentration-time curve from time zero to the last quantifiable concentration (AUClast)
Query!
Assessment method [3]
0
0
AUC(0-last)
Query!
Timepoint [3]
0
0
Day 1- Day 57
Query!
Secondary outcome [4]
0
0
Time to Cmax
Query!
Assessment method [4]
0
0
tmax
Query!
Timepoint [4]
0
0
Day 1 - Day 57
Query!
Secondary outcome [5]
0
0
Terminal half-life
Query!
Assessment method [5]
0
0
t½
Query!
Timepoint [5]
0
0
Day 1 - Day 57
Query!
Secondary outcome [6]
0
0
Volume of distribution during terminal phase after intravenous administration
Query!
Assessment method [6]
0
0
Vz
Query!
Timepoint [6]
0
0
Day 1 - Day 57
Query!
Secondary outcome [7]
0
0
Terminal elimination rate constant
Query!
Assessment method [7]
0
0
Kel
Query!
Timepoint [7]
0
0
Day 1 - Day 57
Query!
Secondary outcome [8]
0
0
Total serum clearance of drug after intravenous administration
Query!
Assessment method [8]
0
0
CL
Query!
Timepoint [8]
0
0
Day 1 - Day 57
Query!
Secondary outcome [9]
0
0
AEs and AESI
Query!
Assessment method [9]
0
0
infusion-related reactions, meningococcal infections, and other serious systemic infections
Query!
Timepoint [9]
0
0
Day 1 - Day 57
Query!
Secondary outcome [10]
0
0
Incidence of Treatment-Emergent changes in safety clinical laboratory parameters from baseline and Grade 3 laboratory abnormalities - Hematology
Query!
Assessment method [10]
0
0
Platelet count, Red blood cell count, Neutrophils, Hemoglobin, Lymphocytes, Hematocrit, Monocytes, Eosinophils, Mean corpuscular volume, Basophils, Mean corpuscular hemoglobin, Mean cell hemoglobin concentration will be measured to assess changes in hematological parameters in blood samples. Any clinically significant pathology results (that require reporting as an adverse event) will be incorporated into the adverse event table.
Query!
Timepoint [10]
0
0
Day 1 - Day 57
Query!
Secondary outcome [11]
0
0
Incidence of Treatment-Emergent changes in safety clinical laboratory parameters from baseline and Grade 3 laboratory abnormalities - Coagulation - International normalized ratio
Query!
Assessment method [11]
0
0
International normalized ratio (INR) will be measured in blood samples. Any clinically significant pathology results (that require reporting as an adverse event) will be incorporated into the adverse event table.
Query!
Timepoint [11]
0
0
Day 1 - Day 57
Query!
Secondary outcome [12]
0
0
Incidence of Treatment-Emergent changes in safety clinical laboratory parameters from baseline and Grade 3 laboratory abnormalities - Coagulation - Activated partial thromboplastin time
Query!
Assessment method [12]
0
0
Activated partial thromboplastin time (sec) will be measured in blood samples. Any clinically significant pathology results (that require reporting as an adverse event) will be incorporated into the adverse event table.
Query!
Timepoint [12]
0
0
Day 1 - Day 57
Query!
Secondary outcome [13]
0
0
Incidence of Treatment-Emergent changes in safety clinical laboratory parameters from baseline and Grade 3 laboratory abnormalities - Coagulation - Prothrombin time
Query!
Assessment method [13]
0
0
Prothrombin time (sec) will be measured in blood samples. Any clinically significant pathology results (that require reporting as an adverse event) will be incorporated into the adverse event table.
Query!
Timepoint [13]
0
0
Day 1 - Day 57
Query!
Secondary outcome [14]
0
0
Incidence of Treatment-Emergent changes in safety clinical laboratory parameters from baseline and Grade 3 laboratory abnormalities - Clinical chemistry - Urea
Query!
Assessment method [14]
0
0
Urea (mmol/L) will be measured in blood samples. Any clinically significant pathology results (that require reporting as an adverse event) will be incorporated into the adverse event table.
Query!
Timepoint [14]
0
0
Day 1 - Day 57
Query!
Secondary outcome [15]
0
0
Incidence of Treatment-Emergent changes in safety clinical laboratory parameters from baseline and Grade 3 laboratory abnormalities - Clinical chemistry - Carbon dioxide (bicarbonate)
Query!
Assessment method [15]
0
0
Carbon dioxide (bicarbonate)(mmol/L) will be measured in blood samples. Any clinically significant pathology results (that require reporting as an adverse event) will be incorporated into the adverse event table.
Query!
Timepoint [15]
0
0
Day 1 - Day 57
Query!
Secondary outcome [16]
0
0
Incidence of Treatment-Emergent changes in safety clinical laboratory parameters from baseline and Grade 3 laboratory abnormalities - Clinical chemistry - Creatinine
Query!
Assessment method [16]
0
0
Creatinine (mcmol/L) will be measured in blood samples. Any clinically significant pathology results (that require reporting as an adverse event) will be incorporated into the adverse event table.
Query!
Timepoint [16]
0
0
Day 1 - Day 57
Query!
Secondary outcome [17]
0
0
Incidence of Treatment-Emergent changes in safety clinical laboratory parameters from baseline and Grade 3 laboratory abnormalities - Clinical chemistry - AST
Query!
Assessment method [17]
0
0
AST (U/L) will be measured in blood samples. Any clinically significant pathology results (that require reporting as an adverse event) will be incorporated into the adverse event table.
Query!
Timepoint [17]
0
0
Day 1 - Day 57
Query!
Secondary outcome [18]
0
0
Incidence of Treatment-Emergent changes in safety clinical laboratory parameters from baseline and Grade 3 laboratory abnormalities - Clinical chemistry - ALT
Query!
Assessment method [18]
0
0
ALT (U/L) will be measured in blood samples. Any clinically significant pathology results (that require reporting as an adverse event) will be incorporated into the adverse event table.
Query!
Timepoint [18]
0
0
Day 1 - Day 57
Query!
Secondary outcome [19]
0
0
Incidence of Treatment-Emergent changes in safety clinical laboratory parameters from baseline and Grade 3 laboratory abnormalities - Clinical chemistry - ALP
Query!
Assessment method [19]
0
0
ALP (U/L) will be measured in blood samples. Any clinically significant pathology results (that require reporting as an adverse event) will be incorporated into the adverse event table.
Query!
Timepoint [19]
0
0
Day 1 - Day 57
Query!
Secondary outcome [20]
0
0
Incidence of Treatment-Emergent changes in safety clinical laboratory parameters from baseline and Grade 3 laboratory abnormalities - Clinical chemistry - Glucose (fasting)
Query!
Assessment method [20]
0
0
Glucose (fasting)(mcmol/L) will be measured in blood samples. Any clinically significant pathology results (that require reporting as an adverse event) will be incorporated into the adverse event table.
Query!
Timepoint [20]
0
0
Day 1 - Day 57
Query!
Secondary outcome [21]
0
0
Incidence of Treatment-Emergent changes in safety clinical laboratory parameters from baseline and Grade 3 laboratory abnormalities - Clinical chemistry - Gamma glutamyl transferase
Query!
Assessment method [21]
0
0
Gamma glutamyl transferase (U/L) will be measured in blood samples. Any clinically significant pathology results (that require reporting as an adverse event) will be incorporated into the adverse event table.
Query!
Timepoint [21]
0
0
Day 1 - Day 57
Query!
Secondary outcome [22]
0
0
Incidence of Treatment-Emergent changes in safety clinical laboratory parameters from baseline and Grade 3 laboratory abnormalities - Clinical chemistry - Total Protein
Query!
Assessment method [22]
0
0
Total protein (g/L) will be measured in blood samples. Any clinically significant pathology results (that require reporting as an adverse event) will be incorporated into the adverse event table.
Query!
Timepoint [22]
0
0
Day 1 - Day 57
Query!
Secondary outcome [23]
0
0
Incidence of Treatment-Emergent changes in safety clinical laboratory parameters from baseline and Grade 3 laboratory abnormalities - Clinical chemistry - Creatine kinase
Query!
Assessment method [23]
0
0
Creatine kinase (U/L) will be measured in blood samples. Any clinically significant pathology results (that require reporting as an adverse event) will be incorporated into the adverse event table.
Query!
Timepoint [23]
0
0
Day 1 - Day 57
Query!
Secondary outcome [24]
0
0
Incidence of Treatment-Emergent changes in safety clinical laboratory parameters from baseline and Grade 3 laboratory abnormalities - Clinical chemistry - Potassium
Query!
Assessment method [24]
0
0
Potassium (mmol/L) will be measured in blood samples. Any clinically significant pathology results (that require reporting as an adverse event) will be incorporated into the adverse event table.
Query!
Timepoint [24]
0
0
Day 1 - Day 57
Query!
Secondary outcome [25]
0
0
Incidence of Treatment-Emergent changes in safety clinical laboratory parameters from baseline and Grade 3 laboratory abnormalities - Clinical chemistry - Lactate dehydrogenase
Query!
Assessment method [25]
0
0
Lactate dehydrogenase (U/L) will be measured in blood samples. Any clinically significant pathology results (that require reporting as an adverse event) will be incorporated into the adverse event table.
Query!
Timepoint [25]
0
0
Day 1 - Day 57
Query!
Secondary outcome [26]
0
0
Incidence of Treatment-Emergent changes in safety clinical laboratory parameters from baseline and Grade 3 laboratory abnormalities - Clinical chemistry - Sodium
Query!
Assessment method [26]
0
0
Sodium (mmol/L) will be measured in blood samples. Any clinically significant pathology results (that require reporting as an adverse event) will be incorporated into the adverse event table.
Query!
Timepoint [26]
0
0
Day 1 - Day 57
Query!
Secondary outcome [27]
0
0
Incidence of Treatment-Emergent changes in safety clinical laboratory parameters from baseline and Grade 3 laboratory abnormalities - Clinical chemistry - Albumin
Query!
Assessment method [27]
0
0
Albumin (g/L) will be measured in blood samples. Any clinically significant pathology results (that require reporting as an adverse event) will be incorporated into the adverse event table.
Query!
Timepoint [27]
0
0
Day 1 - Day 57
Query!
Secondary outcome [28]
0
0
Incidence of Treatment-Emergent changes in safety clinical laboratory parameters from baseline and Grade 3 laboratory abnormalities - Clinical chemistry - Chloride
Query!
Assessment method [28]
0
0
Chloride (mmol/L) will be measured in blood samples. Any clinically significant pathology results (that require reporting as an adverse event) will be incorporated into the adverse event table.
Query!
Timepoint [28]
0
0
Day 1 - Day 57
Query!
Secondary outcome [29]
0
0
Incidence of Treatment-Emergent changes in safety clinical laboratory parameters from baseline and Grade 3 laboratory abnormalities - Clinical chemistry - Total and direct bilirubin
Query!
Assessment method [29]
0
0
Total and direct bilirubin (mcmol/L) will be measured in blood samples. Any clinically significant pathology results (that require reporting as an adverse event) will be incorporated into the adverse event table.
Query!
Timepoint [29]
0
0
Day 1 - Day 57
Query!
Secondary outcome [30]
0
0
Incidence of Treatment-Emergent changes in safety clinical laboratory parameters from baseline and Grade 3 laboratory abnormalities - Clinical chemistry - Calcium
Query!
Assessment method [30]
0
0
Calcium (mmol/L) will be measured in blood samples. Any clinically significant pathology results (that require reporting as an adverse event) will be incorporated into the adverse event table.
Query!
Timepoint [30]
0
0
Day 1 - Day 57
Query!
Secondary outcome [31]
0
0
Incidence of Treatment-Emergent changes in safety clinical laboratory parameters from baseline and Grade 3 laboratory abnormalities - Clinical chemistry - Triglycerides
Query!
Assessment method [31]
0
0
Triglycerides (mmol/L) will be measured in blood samples. Any clinically significant pathology results (that require reporting as an adverse event) will be incorporated into the adverse event table.
Query!
Timepoint [31]
0
0
Day 1 - Day 57
Query!
Secondary outcome [32]
0
0
Incidence of Treatment-Emergent changes in safety clinical laboratory parameters from baseline and Grade 3 laboratory abnormalities - Clinical chemistry - Phosphate
Query!
Assessment method [32]
0
0
Phosphate (mmol/L) will be measured in blood samples. Any clinically significant pathology results (that require reporting as an adverse event) will be incorporated into the adverse event table.
Query!
Timepoint [32]
0
0
Day 1 - Day 57
Query!
Secondary outcome [33]
0
0
Incidence of Treatment-Emergent changes in safety clinical laboratory parameters from baseline and Grade 3 laboratory abnormalities - Clinical chemistry - Cholesterol
Query!
Assessment method [33]
0
0
Cholesterol (mmol/L) will be measured in blood samples. Any clinically significant pathology results (that require reporting as an adverse event) will be incorporated into the adverse event table.
Query!
Timepoint [33]
0
0
Day 1 - Day 57
Query!
Secondary outcome [34]
0
0
Incidence of Treatment-Emergent changes in safety clinical laboratory parameters from baseline and Grade 3 laboratory abnormalities - Urinanalysis - Leukocytes
Query!
Assessment method [34]
0
0
Leukocytes, will be measured to assess changes in urine-related parameters in urine samples. Any clinically significant pathology results (that require reporting as an adverse event) will be incorporated into the adverse event table.
Query!
Timepoint [34]
0
0
Day 1 - Day 57
Query!
Secondary outcome [35]
0
0
Incidence of Treatment-Emergent changes in safety clinical laboratory parameters from baseline and Grade 3 laboratory abnormalities - Urinanalysis - Red blood cells
Query!
Assessment method [35]
0
0
Red blood cells (/hpf) will be measured to assess changes in urine-related parameters in urine samples. Any clinically significant pathology results (that require reporting as an adverse event) will be incorporated into the adverse event table.
Query!
Timepoint [35]
0
0
Day 1 - Day 57
Query!
Secondary outcome [36]
0
0
Incidence of Treatment-Emergent changes in safety clinical laboratory parameters from baseline and Grade 3 laboratory abnormalities - Urinanalysis - Protein
Query!
Assessment method [36]
0
0
Protein (mg/dL) will be measured to assess changes in urine-related parameters in urine samples. Any clinically significant pathology results (that require reporting as an adverse event) will be incorporated into the adverse event table.
Query!
Timepoint [36]
0
0
Day 1 - Day 57
Query!
Secondary outcome [37]
0
0
Incidence of Treatment-Emergent changes in safety clinical laboratory parameters from baseline and Grade 3 laboratory abnormalities - Urinanalysis - pH
Query!
Assessment method [37]
0
0
pH will be measured to assess changes in urine-related parameters in urine samples. Any clinically significant pathology results (that require reporting as an adverse event) will be incorporated into the adverse event table.
Query!
Timepoint [37]
0
0
Day 1 - Day 57
Query!
Secondary outcome [38]
0
0
Incidence of Treatment-Emergent changes in safety clinical laboratory parameters from baseline and Grade 3 laboratory abnormalities - Urinanalysis - Bilirubin
Query!
Assessment method [38]
0
0
Bilirubin will be measured to assess changes in urine-related parameters in urine samples. Any clinically significant pathology results (that require reporting as an adverse event) will be incorporated into the adverse event table.
Query!
Timepoint [38]
0
0
Day 1 - Day 57
Query!
Secondary outcome [39]
0
0
Incidence of Treatment-Emergent changes in safety clinical laboratory parameters from baseline and Grade 3 laboratory abnormalities - Urinanalysis - Nitrite
Query!
Assessment method [39]
0
0
Nitrite will be measured to assess changes in urine-related parameters in urine samples. Any clinically significant pathology results (that require reporting as an adverse event) will be incorporated into the adverse event table.
Query!
Timepoint [39]
0
0
Day 1 - Day 57
Query!
Secondary outcome [40]
0
0
Incidence of Treatment-Emergent changes in safety clinical laboratory parameters from baseline and Grade 3 laboratory abnormalities - Urinanalysis - Urobilinogen
Query!
Assessment method [40]
0
0
Urobilinogen (EU/dl) will be measured to assess changes in urine-related parameters in urine samples. Any clinically significant pathology results (that require reporting as an adverse event) will be incorporated into the adverse event table.
Query!
Timepoint [40]
0
0
Day 1 - Day 57
Query!
Secondary outcome [41]
0
0
Incidence of Treatment-Emergent changes in safety clinical laboratory parameters from baseline and Grade 3 laboratory abnormalities - Urinanalysis - Specific gravity
Query!
Assessment method [41]
0
0
Specific gravity will be measured to assess changes in urine-related parameters in urine samples. Any clinically significant pathology results (that require reporting as an adverse event) will be incorporated into the adverse event table.
Query!
Timepoint [41]
0
0
Day 1 - Day 57
Query!
Secondary outcome [42]
0
0
Incidence of Treatment-Emergent changes in safety clinical laboratory parameters from baseline and Grade 3 laboratory abnormalities - Urinanalysis - Ketones
Query!
Assessment method [42]
0
0
Ketones (mg/dL) will be measured to assess changes in urine-related parameters in urine samples. Any clinically significant pathology results (that require reporting as an adverse event) will be incorporated into the adverse event table.
Query!
Timepoint [42]
0
0
Day 1 - Day 57
Query!
Secondary outcome [43]
0
0
Incidence of Treatment-Emergent changes in safety clinical laboratory parameters from baseline and Grade 3 laboratory abnormalities - Urinanalysis - Glucose
Query!
Assessment method [43]
0
0
Glucose (mg/dL) will be measured to assess changes in urine-related parameters in urine samples. Any clinically significant pathology results (that require reporting as an adverse event) will be incorporated into the adverse event table.
Query!
Timepoint [43]
0
0
Day 1 - Day 57
Query!
Secondary outcome [44]
0
0
Incidence of Treatment-Emergent changes in safety clinical laboratory parameters from baseline and Grade 3 laboratory abnormalities - Urinanalysis - Microscopy
Query!
Assessment method [44]
0
0
Microscopic (if clinically indicated)(/hpf) analyses to assess changes in urine-related parameters in urine samples. Any clinically significant pathology results (that require reporting as an adverse event) will be incorporated into the adverse event table.
Query!
Timepoint [44]
0
0
Day 1 - Day 57
Query!
Secondary outcome [45]
0
0
Changes in vital signs - Blood Pressure
Query!
Assessment method [45]
0
0
Systolic and diastolic blood pressure will be assessed with a completely automated device. Wherever possible, vital signs measurements must be taken using the same body position at subsequent visits and consistent methods between participants.
Query!
Timepoint [45]
0
0
Day 1 - Day 57
Query!
Secondary outcome [46]
0
0
Changes in vital signs - Pulse rate
Query!
Assessment method [46]
0
0
Pulse rate will be assessed with a completely automated device. Wherever possible, vital signs measurements must be taken using the same body position at subsequent visits and consistent methods between participants.
Query!
Timepoint [46]
0
0
Day 1 - Day 57
Query!
Secondary outcome [47]
0
0
Changes in vital signs - Body Temperature
Query!
Assessment method [47]
0
0
Body temperature (aural is preferred), will be assessed with a completely automated device. Wherever possible, vital signs measurements must be taken using the same body position at subsequent visits and consistent methods between participants.
Query!
Timepoint [47]
0
0
Day 1 - Day 57
Query!
Secondary outcome [48]
0
0
Changes in Electrocardiograms (ECG) - Heart rate
Query!
Assessment method [48]
0
0
Single 12-lead ECGs will be obtained after the participant has rested comfortably in the supine position for at least 5 minutes in a quiet setting without distractions (eg, television, cell phones) using an ECG machine that automatically calculates the heart rate. All ECG data will be documented at each prespecified time point, and the details will be recorded in both the source documents and the eCRF. The Investigator (or a qualified delegate at the investigational site) will interpret the ECG using 1 of the following categories: normal, abnormal not clinically significant, or abnormal clinically significant and record their evaluation in the eCRF.
Query!
Timepoint [48]
0
0
Day 1 - Day 57
Query!
Secondary outcome [49]
0
0
Changes in Electrocardiograms (ECG) - PR interval
Query!
Assessment method [49]
0
0
Single 12-lead ECGs will be obtained after the participant has rested comfortably in the supine position for at least 5 minutes in a quiet setting without distractions (eg, television, cell phones) using an ECG machine that automatically measures PR interval. All ECG data will be documented at each prespecified time point, and the details will be recorded in both the source documents and the eCRF. The Investigator (or a qualified delegate at the investigational site) will interpret the ECG using 1 of the following categories: normal, abnormal not clinically significant, or abnormal clinically significant and record their evaluation in the eCRF.
Query!
Timepoint [49]
0
0
Day 1 - Day 57
Query!
Secondary outcome [50]
0
0
Changes in Electrocardiograms (ECG) - RR interval
Query!
Assessment method [50]
0
0
Single 12-lead ECGs will be obtained after the participant has rested comfortably in the supine position for at least 5 minutes in a quiet setting without distractions (eg, television, cell phones) using an ECG machine that automatically measures RR interval. All ECG data will be documented at each prespecified time point, and the details will be recorded in both the source documents and the eCRF. The Investigator (or a qualified delegate at the investigational site) will interpret the ECG using 1 of the following categories: normal, abnormal not clinically significant, or abnormal clinically significant and record their evaluation in the eCRF.
Query!
Timepoint [50]
0
0
Day 1 - Day 57
Query!
Secondary outcome [51]
0
0
Changes in Electrocardiograms (ECG) - QRS duration
Query!
Assessment method [51]
0
0
Single 12-lead ECGs will be obtained after the participant has rested comfortably in the supine position for at least 5 minutes in a quiet setting without distractions (eg, television, cell phones) using an ECG machine that automatically measures QRS duration. All ECG data will be documented at each prespecified time point, and the details will be recorded in both the source documents and the eCRF. The Investigator (or a qualified delegate at the investigational site) will interpret the ECG using 1 of the following categories: normal, abnormal not clinically significant, or abnormal clinically significant and record their evaluation in the eCRF.
Query!
Timepoint [51]
0
0
Day 1 - Day 57
Query!
Secondary outcome [52]
0
0
Changes in Electrocardiograms (ECG) - QT interval
Query!
Assessment method [52]
0
0
Single 12-lead ECGs will be obtained after the participant has rested comfortably in the supine position for at least 5 minutes in a quiet setting without distractions (eg, television, cell phones) using an ECG machine that automatically measures QT interval. The QT interval corrected for heart rate by Fridericia's formula (QTcF interval) will be derived. All ECG data will be documented at each prespecified time point, and the details will be recorded in both the source documents and the eCRF. The Investigator (or a qualified delegate at the investigational site) will interpret the ECG using 1 of the following categories: normal, abnormal not clinically significant, or abnormal clinically significant and record their evaluation in the eCRF.
Query!
Timepoint [52]
0
0
Day 1 - Day 57
Query!
Secondary outcome [53]
0
0
Number of patients with treatment-related adverse events as assessed by CTCAE v4.0 via physical examination
Query!
Assessment method [53]
0
0
Complete physical examination will be performed by a study-delegated registered physician at Screening and will include, at a minimum, assessments of general appearance, head, ears, eyes, nose, throat, neck (including thyroid), skin, cardiovascular system, respiratory, system, gastrointestinal system, musculoskeletal system, lymph nodes, and nervous system. A brief physical examination will be performed at specified time points outlined in the SoA and will include, at a minimum, assessments of the skin, lungs, cardiovascular system, and abdomen (liver and spleen). A symptom-directed physical examination, including areas with previously noted abnormalities and/or that are associated with any new complaints from the participant, will be performed at all other visits and at any time throughout the study, as clinically indicated.
Query!
Timepoint [53]
0
0
Day 1 - Day 57
Query!
Secondary outcome [54]
0
0
Comparison of the immunogenicity of TUR03 and Soliris following a single IV infusion in healthy participants - Frequency of antidrug antibodies (ADAs)
Query!
Assessment method [54]
0
0
Frequency of ADAs will be assessed. Serum samples will be screened for antibodies binding to eculizumab in TUR03 and Soliris. The detection and characterization of ADAs to eculizumab will be performed using validated immunoassay methods.
Query!
Timepoint [54]
0
0
Day 1 - Day 57
Query!
Secondary outcome [55]
0
0
Comparison of the immunogenicity of TUR03 and Soliris following a single IV infusion in healthy participants - Antidrug antibody titers
Query!
Assessment method [55]
0
0
Titers of ADAs will be assessed.
Query!
Timepoint [55]
0
0
Day 1 - Day 57
Query!
Secondary outcome [56]
0
0
Comparison of the immunogenicity of TUR03 and Soliris following a single IV infusion in healthy participants - Neutralizing antibodies (NAbs)
Query!
Assessment method [56]
0
0
The frequency of NAbs will be assessed in ADA-positive participants' sera. Subsequent to the confirmation of ADA-positivity, antibodies will be further characterized and evaluated for their ability to neutralize the activity of the IP (TUR03 and Soliris).
Query!
Timepoint [56]
0
0
Day 1 - Day 57
Query!
Secondary outcome [57]
0
0
PD profile of TUR03 and Soliris - ABEC (0-1344) CH50
Query!
Assessment method [57]
0
0
Area between the baseline and effect curves for hemolytic complement activity from 0 to 1344 hours
Query!
Timepoint [57]
0
0
Day 1 - Day 57
Query!
Secondary outcome [58]
0
0
PD profile of TUR03 and Soliris - AUEC(0-1344) CH50
Query!
Assessment method [58]
0
0
Area under the effect curve for hemolytic complement activity from 0 to 1344 hours
Query!
Timepoint [58]
0
0
Day 1 - Day 57
Query!
Secondary outcome [59]
0
0
PD profile of TUR03 and Soliris - Emin CH50
Query!
Assessment method [59]
0
0
Minimum hemolytic complement activity from 0 to 1344 hours
Query!
Timepoint [59]
0
0
Day 1 - Day 57
Query!
Secondary outcome [60]
0
0
PD profile of TUR03 and Soliris - Tmin CH50
Query!
Assessment method [60]
0
0
Time to minimum hemolytic complement activity from 0 to 1344 hours
Query!
Timepoint [60]
0
0
Day 1 - Day 57
Query!
Eligibility
Key inclusion criteria
Participants are eligible to be included in the study only if ALL of the following criteria apply:
1. Capable of giving signed informed consent as described in Section 10.1, which includes compliance with the requirements and restrictions listed in the Informed Consent Form (ICF) and in this protocol.
2. Participants assigned male at birth who are =18 years and =45 years old at the time of signing the ICF.
3. Body weight =50 kg and =90 kg and body mass index (BMI) =18.00 kg/m2 and =30.00 kg/m2 at Screening and Day -1.
4. Participants must be healthy as determined by the Investigator, based on medical history, physical examination, vital signs, ECG, and clinical laboratory evaluations at Screening and Day -1, as follows:
1. Hematology and coagulation results within reference ranges.
2. Liver function panel analyte values =1.5 × upper limits of normal (ULN), which include aspartate transaminase, alanine transaminase, and total bilirubin (for participants with Gilbert's Syndrome, total bilirubin =3.0 × ULN is allowed if direct bilirubin is =50%), alkaline phosphatase, and gamma glutamyl transferase at Screening.
3. Urinalysis within reference ranges or showing no clinically significant findings.
NOTE: One repeat of clinical laboratory tests is allowed at the discretion of the Investigator.
5. Participants must have documented evidence of prior complete vaccination with meningococcal vaccines against N. meningitidis serogroup B at any time and against serogroups A, C, W, and Y within 5 years prior to Screening in line with local immunization requirements or must agree to be vaccinated against N. meningitidis during the study.
6. Nonsterilized participants with partners of childbearing potential must agree to take appropriate contraceptive measures (as described in Section 10.4) from Day 1 until 5 months after IP administration and refrain from donating sperm during this period. NOTE: Participants with pregnant partners are excluded.
7. Nonsmoker or occasional smoker, ie, smokes =10 cigarettes (or equivalent of tobacco- or nicotine-containing products) per week within 30 days prior to Screening and is able to abide by the smoking policy of the study site.
8. Ability and willingness to abstain from alcohol from 48 hours before admission to the study site on Day -1, during in-house observation at the study site until discharge, and for 24 hours prior to ambulatory visits.
Query!
Minimum age
18
Years
Query!
Query!
Maximum age
45
Years
Query!
Query!
Sex
Males
Query!
Can healthy volunteers participate?
Yes
Query!
Key exclusion criteria
Participants are excluded from the study if ANY of the following criteria apply:
1. Known or suspected hereditary or acquired complement deficiency.
2. History of meningococcal infection.
3. History or evidence of a clinically significant disorder (including psychiatric disorders), condition, or disease that, in the opinion of the Investigator and Medical Monitor or designee, would pose a risk to participant safety or interfere with the study evaluation, procedures, or completion. EXCEPTION: Fully resolved childhood asthma is not exclusionary.
4. History of splenectomy.
5. History of surgery or major trauma within 12 weeks of Screening, or surgery planned during the study.
6. A recent history (within 1 week prior to IP administration) or presence or suspicion of current active systemic or local infection, a known risk for developing sepsis, and/or known active inflammatory condition, in the opinion of the Investigator.
7. History of or current invasive malignancy (excluding basal or squamous cell carcinoma that has been fully resected with no evidence of metastatic disease for 1 year).
8. History of ongoing seborrheic dermatitis or eczema.
9. History of clinically significant headaches that, in the opinion of the Investigator, would pose a risk to participant safety or interfere with the study evaluation, procedures, or completion.
10. History of recurrent/chronic hemorrhages or any hemorrhage within 30 days prior to IP administration.
11. History of a drug- or food-induced severe hypersensitivity reaction (eg, immunologic or nonimmunologic anaphylaxis).
12. Known hypersensitivity reaction to penicillin and/or cephalosporin that, in the opinion of the Investigator, would pose a risk to participant safety.
13. Known hypersensitivity to any component of TUR03 or Soliris, murine proteins, or other monoclonal antibodies.
14. Known hypersensitivity to any component of meningococcal vaccines, including those containing diphtheria toxoid, or a life-threatening reaction after previous administration of a vaccine containing similar components.
15. Hypertension at Screening or Day -1 (defined as a systolic blood pressure [BP] >140 mm Hg and/or a diastolic BP >90 mm Hg, confirmed by a single repeat measurement that same day) or a history of hypertension requiring pharmacological intervention.
16. Proteinuria at Screening or Day -1 (with a urine dipstick value of 1+ or above)..
17. Tests positive for human immunodeficiency virus (HIV 1 and 2), hepatitis B virus surface antigen, hepatitis B core antibody, or hepatitis C virus.
18. Tests positive for tuberculosis (TB) using the QuantiFERON®-TB Gold test at Screening or, if indeterminant result on the first test, tests positive or indeterminant on repeat QuantiFERON-TB Gold test.
19. Positive screen for alcohol by breath test and/or potential drugs of abuse by urine drug screen at Screening or Day -1. NOTE: One repeat screen is allowed at the discretion of the Investigator.
20. History of alcohol or drug abuse or drug addiction (including cannabis products) within the last 12 months prior to Screening.
21. Prior exposure to eculizumab or similar compounds (ie, a monoclonal antibody that specifically binds to the complement protein C5).
22. Use of immunoglobulins or iron supplementation within 3 months prior to Screening.
23. Use of any over-the-counter (OTC) medications, herbal remedies such as St. John's Wort extract, or prescription medications within 7 days or 5 half lives (whichever is longer) prior to IP administration. EXCEPTIONS: Vitamins, dietary supplements, and paracetamol (up to 4 g per day, but <1 g in 4 hours) for analgesia are not exclusionary.
24. Use of other investigational drugs (or is currently using an investigational device) within 60 days or 5 half-lives (whichever is longer) prior to IP administration.
25. Vaccination with a live vaccine within 30 days prior to IP administration, or vaccination with an inactivated vaccine or approved COVID-19 vaccine within 14 days prior to IP administration, or planning to get vaccinated during the study period. EXCEPTIONS: Receipt of required meningococcal vaccinations per protocol is not exclusionary.
26. Veins unsuitable for venous blood collection.
27. Donated blood (including blood products) or experienced loss of blood =500 mL within 30 days of Screening, or donated plasma within 7 days of Screening.
28. Participant is a family member or employee of the Investigator or Sponsor.
Query!
Study design
Purpose of the study
Other
Query!
Allocation to intervention
Randomised controlled trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Blinded (masking used)
Query!
Who is / are masked / blinded?
The people receiving the treatment/s
The people analysing the results/data
Query!
Query!
Query!
Query!
Intervention assignment
Parallel
Query!
Other design features
Query!
Phase
Phase 1
Query!
Type of endpoint/s
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Recruiting
Query!
Data analysis
Query!
Reason for early stopping/withdrawal
Query!
Other reasons
Query!
Date of first participant enrolment
Anticipated
Query!
Actual
10/04/2023
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
5/10/2024
Query!
Actual
Query!
Sample size
Target
120
Query!
Accrual to date
Query!
Final
Query!
Recruitment in Australia
Recruitment state(s)
QLD
Query!
Recruitment hospital [1]
0
0
Q-Pharm Pty Limited - Herston
Query!
Recruitment postcode(s) [1]
0
0
- Herston
Query!
Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Query!
Name
Turgut Ardika PTY LTD
Query!
Address
Query!
Country
Query!
Ethics approval
Ethics application status
Query!
Summary
Brief summary
This study is designed as a randomized, double-blind, parallel-group study to evaluate the PK, safety, tolerability, immunogenicity, and PD of TUR03 compared to Soliris, when administered as a single IV infusion in healthy adult male participants.
Query!
Trial website
https://clinicaltrials.gov/study/NCT05863442
Query!
Trial related presentations / publications
Query!
Public notes
Query!
Contacts
Principal investigator
Name
0
0
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for public queries
Name
0
0
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for scientific queries
No information has been provided regarding IPD availability
What supporting documents are/will be available?
No Supporting Document Provided
Results publications and other study-related documents
No documents have been uploaded by study researchers.
Results not provided in
https://clinicaltrials.gov/study/NCT05863442
Download to PDF